Davis's Drug Guide
mobocertinib
General
Genetic Implications:
**Off Market Drug**
This medication is no longer available in the United States. Information provided here is for reference purposes only.
Pronunciation:
moe-boe-ser-ti-nib
Trade Name(s)
- Exkivity
Ther. Class.
Pharm. Class.
epidermal growth factor receptor (EGFR) inhibitors
kinase inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Mobocertinib." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2024. Nursing Central, nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110944/5/mobocertinib.
Vallerand AHA, Sanoski CAC, Quiring CC. Mobocertinib. Davis's Drug Guide. F.A. Davis Company; 2024. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110944/5/mobocertinib. Accessed October 13, 2024.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2024). Mobocertinib. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110944/5/mobocertinib
Vallerand AHA, Sanoski CAC, Quiring CC. Mobocertinib [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2024. [cited 2024 October 13]. Available from: https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110944/5/mobocertinib.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - mobocertinib
ID - 110944
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110944/5/mobocertinib
PB - F.A. Davis Company
ET - 19
DB - Nursing Central
DP - Unbound Medicine
ER -
